Testosterone News and Research

Latest Testosterone News and Research

PCEC to provide free prostate cancer screenings

This September, the Prostate Conditions Education Council reminds men to set aside 10 minutes to take lifesaving measures. In just 10 minutes, the same amount of time it takes to shave their faces, men can be screened for prostate cancer, the second leading cause of death among American men. For one week this month the Prostate Conditions Education Council (PCEC) will be coordinating Prostate Cancer Awareness Week (PCAW), which provides free or low-cost screenings to thousands of men across the United States.

16 Sep 2009

CPEX Pharmaceuticals to discuss the clinical aspects of nasal insulin therapy

CPEX Pharmaceuticals, Inc. (“CPEX”) today announced that it will participate in the Ninth Annual Diabetes Technology Meeting to be held November 5–7, 2009, at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to present an oral presentation titled “The Technology and Clinical Aspects of Nasal Insulin Therapy” at 9:30 a.m. PST on Saturday, November 7, 2009.

15 Sep 2009

"High Five" factors in overweight men impacts their energy and health: Building Healthier America

For overweight men ages 45 and older, the "High Five" factors of high cholesterol, high blood pressure, high blood sugar/glucose, poor diet and low testosterone may be impacting their energy and health, sabotaging efforts to lose weight, according to Building Healthier America, a national nonprofit organization dedicated to reversing the negative trends of overweight and obesity in the U.S.

15 Sep 2009

Prostate cancer treatment options discussed in a study

A new study in the Journal of the American Medical Association (JAMA) appears to support the theory outlined in earlier studies that men with more advanced forms of prostate cancer don't benefit from a combination of hormone and radiation therapy.

9 Sep 2009

Biosante and Cell Genesys to merge after stockholders' approval

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the previously announced merger between the companies. On June 29, 2009, BioSante and Cell Genesys entered into a definitive merger agreement by which the companies will merge in an all-stock transaction, with BioSante as the surviving company.

3 Sep 2009

Biosante Pharmaceuticals and Cell Genesys to hold stockholders meeting for merger approval

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. (NASDAQ:CEGE), today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the previously announced merger between the companies.

3 Sep 2009

Biosante's CEO to present an overview of the company and its impending merger with Cell Genesys

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, its president and CEO will present an overview of the company and its impending merger with Cell Genesys (NASDAQ: CEGE) at two healthcare investment and partnering conferences during the month of September.

3 Sep 2009

FDA extends review period for Endo Pharmaceuticals' testosterone undecanoate

Endo Pharmaceuticals announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the agency has extended its review period for its long-acting testosterone undecanoate injection for men diagnosed with hypogonadism, from Sept. 2, 2009 to Dec. 2, 2009.

3 Sep 2009

CORD I phase III clinical trial results of XIAFLEX published

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that The New England Journal of Medicine (NEJM) has published in its September 3rd edition, the Company's pivotal CORD I Phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum) a novel, first-in-class, biologic for the nonsurgical treatment of Dupuytren's contracture.

3 Sep 2009

Polycystic ovary syndrome in women can be relieved by acupuncture and exercise

Polycystic ovary syndrome, a common condition among women, can be relieved by the use of acupuncture and exercise. This has been shown by a recent study at the Sahlgrenska Academy, University of Gothenburg, Sweden.

27 Aug 2009

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

26 Aug 2009

Studies reveal that obese men are at increased risk for erectile dysfunction

Obese men are at increased risk for erectile dysfunction (ED), likely caused by atherosclerosis-related hypertension and cardiovascular disease, as well as hormonal changes associated with obesity, as described in a timely article published in Obesity and Weight Management, a journalzine published by Mary Ann Liebert, Inc.

25 Aug 2009

Increased testosterone levels boost appetite and career choices in women

The battle of the sexes rages on, this time from the trading floor. While there has long been debate about the social and biological differences between men and women, new research by the Kellogg School of Management at Northwestern University, the University of Chicago Booth School of Business and the University of Chicago's Department of Comparative Human Development explores how the hormone testosterone plays an important role in gender differences in financial risk aversion and career choice.

24 Aug 2009

Results of PCF funded study could impact the standard of care for prostate cancer patients

Twice-yearly intravenous infusion with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, was published today in the print edition of the New England Journal of Medicine (NEJM). Both fundamental research on rank ligand (RANKL) in prostate cancer bone metastasis and other molecular factors involved in the denosumab study were supported at Massachusetts General Hospital with funding from the Prostate Cancer Foundation (PCF).

21 Aug 2009

Research attributes accumulation of belly fat to change in hormone balance during menopause transition

In middle-aged women, visceral fat, more commonly called belly fat, is known to be a significant risk factor for cardiovascular disease, but what causes visceral fat to accumulate?

21 Aug 2009

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

AEterna Zentaris Inc. today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

17 Aug 2009

Obesity leads to worse prostate cancer in both black and whites equally

A new look at a large database of prostate cancer patients shows that obesity plays no favorites when it comes to increasing the risk of recurrence after surgery: Being way overweight is equally bad for blacks and whites, say researchers at Duke University Medical Center.

13 Aug 2009

$Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer$

Testosterone News and Research

Latest Testosterone News and Research

PCEC to provide free prostate cancer screenings

CPEX Pharmaceuticals to discuss the clinical aspects of nasal insulin therapy

"High Five" factors in overweight men impacts their energy and health: Building Healthier America

Prostate cancer treatment options discussed in a study

Biosante and Cell Genesys to merge after stockholders' approval

Biosante Pharmaceuticals and Cell Genesys to hold stockholders meeting for merger approval

Biosante's CEO to present an overview of the company and its impending merger with Cell Genesys

FDA extends review period for Endo Pharmaceuticals' testosterone undecanoate

CORD I phase III clinical trial results of XIAFLEX published

Polycystic ovary syndrome in women can be relieved by acupuncture and exercise

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Studies reveal that obese men are at increased risk for erectile dysfunction

Increased testosterone levels boost appetite and career choices in women

Results of PCF funded study could impact the standard of care for prostate cancer patients

Research attributes accumulation of belly fat to change in hormone balance during menopause transition

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

Obesity leads to worse prostate cancer in both black and whites equally

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

Recruitment of new neurons slows when old brain cells kept from dying

Metabolic bone disease in cirrhosis patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Testosterone News and Research

Latest Testosterone News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in